LA
RXRX icon

LVW Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

LVW Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44K Buy
+12,000
New +$40K ﹤0.01% 461
2026
Q1 		– Sell
-13,000
Closed -$53.2K – 454
2025
Q4 		$53.2K Hold
13,000
– – 0.01% 341
2025
Q3 		$63.4K Buy
+13,000
New +$68.3K 0.01% 346

Other funds holding RXRX

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
PL
Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $444M AUM 31.14% 1-Year Est. Return
NWMG
National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $3.65B AUM 26.64% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IIA
Integral Investment Advisors Turlock, California $454M AUM 21.42% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

LVW Advisors's RXRX Position: Q2 2026 in Review

LVW Advisors opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 12,000 shares worth $44K. The stake represents ﹤0.01% of the portfolio and ranks #461 among its holdings. This is a return to the name: LVW Advisors previously reported a position in RXRX as recently as Q4 2025.

LVW Advisors first reported a position in RXRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $63.4K in Q3 2025. 24 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • LVW Advisors held 12,000 shares of Recursion Pharmaceuticals worth $44K as of Q2 2026.
  • Recursion Pharmaceuticals was a new LVW Advisors position in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of LVW Advisors's portfolio in Q2 2026, its #461 holding.
  • LVW Advisors first reported a position in Recursion Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • LVW Advisors's Recursion Pharmaceuticals position peaked at $63.4K in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on LVW Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.